NantHealth, Inc. for Securities Fraud Class Action

VIEW COMPLAINT

Please complete this form and list your purchase and sale transaction(s) for NantHealth, Inc. (Nasdaq: NH) securities between June 1, 2016, and May 1, 2017,both dates inclusive:

You may also contact James Maro, Jr., Esq. toll free at (484) 270-1453, or you may submit your information via email at info@ktmc.com, or you may click here to print a PDF of this form.

Information Sheet

* Denotes required field

First Name *

Last Name *

Email *

Country

City

State\Province

Zip\Postal Code

Country Prefix

Phone Number

Phone Type

Purchase(s)

+ Additional Purchases

Sale(s)

+ Additional Sales

Date

# of Shares

Price per Share

Date

Principal Amount

Amount Paid

Series or CUSIP

Date

# of Contracts

Price per Contract

Exercise Price

Expiration Date

Did you purchase shares of NantHealth, Inc. (2017) prior to the Class Period?

Yes

Are you a current or former employee of NantHealth, Inc. (2017)?

Yes

The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.

I agree to the KTMC
disclaimer

Yes

I would like to receive
new case alerts by email

Yes

Submit Your Information

COMPANY	NantHealth, Inc.
COURT	United States District Court for the Central District of California
CASE NUMBER	17-cv-01825
JUDGE	The Hon. Terry J. Hatter, Jr.
CLASS PERIOD	June 1, 2016, - May 1, 2017
SECURITY TYPE	Common Stock

Case Background:

On March 3, 2017, the initial complaint in this securities class action was filed against NantHealth, Inc. (“NantHealth” or the “Company”), and certain of NantHealth’s directors and officers, asserting violations of sections 10(b) and 20(a) of the Securities Exchange Act. The complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose that: (1) defendants had donated funds through nonprofit organizations to the University of Utah for the purpose of funneling those funds back into NantHealth; (2) as such, the Company and defendants participated in the violation of federal tax laws—exposing the Company to possible civil and criminal liability; (3) the Company improperly recorded orders received from the University of Utah as GPS Cancer test orders; (4) as a result, the Company reported false and inflated GPS Cancer order figures for the third quarter of 2016; and (5) as a result of the foregoing, the Company’s financial statements and defendants’ statements about NantHealth’s business, operations, and prospects, were materially false and misleading.

On July 30, 2019, the Court certified the Class consisting of all persons or entities who purchased or acquired NantHealth common stock in or traceable to NantHealth’s June 1, 2016 Initial Public Offering or purchased or acquired NantHealth common stock between June 1, 2016, and May 1, 2017.

Current Status of Case:

On January 31, 2020, the Court issued an Order of Preliminary Approval of the Settlement. On September 10, 2020, the Court granted Final Approval of the Settlement. This action has concluded.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.